BMS Deploys Claude AI Across 30,000-Person Global Workforce
Bristol Myers Squibb will integrate Claude artificial intelligence across all major business functions, from drug research to manufacturing and corporate operations. The partnership with Anthropic represents a shift from experimental AI projects toward embedding AI directly into daily workflows for more than 30,000 employees worldwide.
Greg Meyers, executive VP and chief digital and technology officer at BMS, said the real opportunity lies in breaking down data silos. "Most enterprise AI stops at the chatbot. The real prize is the untapped value still trapped behind decades of data silos," Meyers said.
Three operational priorities
BMS will focus deployment on three areas where it expects the fastest returns.
Engineering and software development: Claude Code will accelerate how BMS' engineering and data science teams build and deploy capabilities. The tool standardizes development practices across the enterprise.
Drug development workflows: AI agents will be embedded into existing drug development processes. Claude will apply advanced reasoning to decades of BMS' scientific, molecular, and clinical data to accelerate target identification across oncology, hematology, neuroscience, and immunology.
For clinical trials, Claude will handle documentation tasks - drafting study reports, patient safety narratives, and regulatory submissions. The capability could compress the time between data lock and filing, a critical factor in getting new treatments to patients faster.
Manufacturing processes will also see automation. Claude will support root-cause investigations, corrective and preventive action documentation, and batch release decisions. The goal is to maintain quality and compliance while accelerating decision-making.
Institutional knowledge access: Claude will connect to knowledge stored across BMS systems, giving employees access to institutional information while maintaining governance and audit controls for regulatory compliance. Commercial and medical affairs teams will use this capability to deliver more personalized engagement with healthcare professionals.
Building on existing AI infrastructure
This partnership extends more than three years of AI investment at BMS. The company already provides employees with unlimited access to frontier models through an internal platform.
Meyers said the companies that lead the next decade of biopharmaceutical development will be those that operate fundamentally differently with AI. BMS intends to be among them.
Your membership also unlocks:
